Journal
CLINICAL AND EXPERIMENTAL IMMUNOLOGY
Volume 183, Issue 1, Pages 30-36Publisher
WILEY
DOI: 10.1111/cei.12670
Keywords
ankylosing spondylitis; Th17; treatment
Categories
Funding
- Oxford NIHR Biomedical Research Unit
- Oxford NIHR Biomedical Research Centre
Ask authors/readers for more resources
Ankylosing spondylitis (AS), the most common form of spondyloarthropathy, is a chronic, progressive multi-system inflammatory disorder characteristically affecting the sacroiliac joints and axial skeleton. Although the exact mechanisms underlying the pathogenesis of AS remain to be elucidated, the presence of human leucocyte antigen (HLA)-B27 is known to markedly increase its risk of development. Current treatments include non-steroidal anti-inflammatory drugs (NSAIDs) and tumour necrosis factor (TNF) blockers. In recent years, the interleukin (IL)-23/IL-17 pathway has been shown to have significance in the pathogenesis of AS and treatment modalities targeting this pathway have been shown to be beneficial in various other inflammatory conditions. This review provides an overview of the IL-23/IL-17 pathway in the pathogenesis of AS and summarizes new potential treatments for AS and related inflammatory diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available